- Home
- OTLK vs DPRO Comparison
OTLK vs DPRO Comparison
Compare OTLK & DPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- DPRO
- Stock Information
- Founded
- OTLK 2010
- DPRO 1998
- Country
- OTLK United States
- DPRO Canada
- Employees
- OTLK N/A
- DPRO N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- DPRO Aerospace
- Sector
- OTLK Health Care
- DPRO Industrials
- Exchange
- OTLK Nasdaq
- DPRO Nasdaq
- Market Cap
- OTLK 48.3M
- DPRO 38.9M
- IPO Year
- OTLK 2016
- DPRO N/A
- Fundamental
- Price
- OTLK $2.25
- DPRO $5.59
- Analyst Decision
- OTLK Strong Buy
- DPRO Strong Buy
- Analyst Count
- OTLK 5
- DPRO 2
- Target Price
- OTLK $9.60
- DPRO $6.50
- AVG Volume (30 Days)
- OTLK 987.3K
- DPRO 5.7M
- Earning Date
- OTLK 08-13-2025
- DPRO 08-12-2025
- Dividend Yield
- OTLK N/A
- DPRO N/A
- EPS Growth
- OTLK N/A
- DPRO N/A
- EPS
- OTLK 0.83
- DPRO N/A
- Revenue
- OTLK N/A
- DPRO $4,716,450.00
- Revenue This Year
- OTLK N/A
- DPRO $94.01
- Revenue Next Year
- OTLK $419.06
- DPRO $95.14
- P/E Ratio
- OTLK $2.62
- DPRO N/A
- Revenue Growth
- OTLK N/A
- DPRO 7.90
- 52 Week Low
- OTLK $0.87
- DPRO $1.55
- 52 Week High
- OTLK $9.10
- DPRO $7.31
- Technical
- Relative Strength Index (RSI)
- OTLK 67.03
- DPRO 62.60
- Support Level
- OTLK $2.16
- DPRO $3.23
- Resistance Level
- OTLK $2.45
- DPRO $7.31
- Average True Range (ATR)
- OTLK 0.16
- DPRO 0.50
- MACD
- OTLK 0.05
- DPRO 0.27
- Stochastic Oscillator
- OTLK 81.01
- DPRO 54.78
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About DPRO Draganfly Inc.
Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The three segments are Drones, Vital (Vital Intelligence), and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Vital segment derives its revenue from the sale of products that measure vitals to help detect symptoms from large groups of people from a distance. The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.